Gastroparesis - Market Insight, Epidemiology and Market Forecast - 2027

Gastroparesis - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 5 Business Days
  • Publication: Aug, 2018
  • SKU: DIMI0086
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Gastroparesis  - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Gastroparesis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Gastroparesis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered 

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2027
Gastroparesis - Disease Understanding and Treatment Algorithm
According to International Foundation for Functional Gastrointestinal Disorders (IFFGD), Gastroparesis is also called delayed gastric emptying. It is a condition that affects the normal spontaneous movement of the muscles (motility) in stomach. It is defined as a combination of chronic dyspeptic symptoms and delayed emptying of a solid test meal. It remains a difficult-to-treat disorder with a significant impact on quality of life.
The DelveInsight Gastroparesis market report gives the thorough understanding of the Gastroparesis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Gastroparesis in the US, Europe, and Japan.

Gastroparesis Epidemiology
The Gastroparesis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Gender Specific Prevalence, Severity based prevalence and Diagnosed and treatable population] scenario of Gastroparesis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to Digestive Diseases Center, Gastroparesis affects more than 1.5 million Americans, with approximately 100,000 suffering from a severe form of the disorder and standard medical therapy fails to relieve symptoms in approximately 30,000 of these patients.
At least 20 percent of people with type 1 diabetes develop gastroparesis. The disease also occurs in people with type 2 diabetes, although less often.

Gastroparesis Drug Chapters
This segment of the Gastroparesis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market size of Gastroparesis is mainly accounted by the therapeutic categories of prokinetic (promotility) agents (such as Metoclopramide, Domperidone, Erythromycin, Cisapride), antiemetic agents and Botulinum Toxin Injection (nerve blocking agent). Only one drug, Metoclopramide is approved by the U.S. Food and Drug Administration (FDA) for the treatment of gastroparesis. Off-label use is the permissible practice by doctors to prescribe medications for other than their FDA approved intended indications.

Gastroparesis Market Outlook
The Gastroparesis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
Expected launch of emerging therapies such as VLY-686 (Vanda Pharmaceuticals), TAK-906 (Takeda Pharaceutical), Relamorelin (Allergan), TD-8954 (Theravance Biopharma) and other treatments, are shall lead to a significant increase in the market size during the forecast period [2018-2027].

Gastroparesis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Gastroparesis Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Gastroparesis Report Key Strengths

• 10 Years Forecast

• 7MM Coverage 

• Epidemiology Segmentation

• Sub-type Segmentation

• Key Cross Competition 

• Highly Analyzed Market

• Drugs Uptake

Gastroparesis Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Gastroparesis market

• Organize sales and marketing efforts by identifying the best opportunities for Gastroparesis market

• To understand the future market competition in the Gastroparesis market.

1. Report Introduction
2. Gastroparesis Market Overview at a Glance
2.1. 7 Major Market Size (%) of Gastroparesis in 2017
2.2. 7 Major Market Size (%) of Gastroparesis in 2027
3. Disease Background and Overview: Gastroparesis
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent Population of Gastroparesis (2016-2027)
4.3. Gender based prevalence of Gastroparesis in 7MM (2016-2027)
4.4. Severity based (Mild, Moderate, Severe) of Gastroparesis in 7MM (2016-2027)
4.5. Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027)
5. Epidemiology of Gastroparesis& Night Sweats by Countries (2016-2027)
5.1. United States- Epidemiology (2016-2027)
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Gastroparesis in the US (2016-2027)
5.1.3. Gender based prevalence of Gastroparesis in the US (2016-2027)
5.1.4. Severity based Prevalence (Mild, Moderate, Severe) of Gastroparesis in the US (2016-2027)
5.1.5. Diagnosed and Treatable population of Gastroparesis in the US (2016-2027)
5.2. EU-5 - Epidemiology (2016-2027)
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.2.1. Total Prevalent Cases of Gastroparesis in Germany (2016-2027)
5.2.2.2. Gender based prevalence of Gastroparesis in Germany (2016-2027)
5.2.2.3. Severity based Prevalence (Mild, Moderate, Severe) of Gastroparesis in Germany (2016-2027)
5.2.2.4. Diagnosed and Treatable population of Gastroparesis in Germany (2016-2027)
5.2.3. France
5.2.3.1. Total Prevalent Cases of Gastroparesis in France (2016-2027)
5.2.3.2. Gender based prevalence of Gastroparesis in France (2016-2027)
5.2.3.3. Severity based Prevalence (Mild, Moderate, Severe) of Gastroparesis in France (2016-2027)
5.2.3.4. Diagnosed and Treatable population of Gastroparesis in France (2016-2027)
5.2.4. Italy
5.2.4.1. Total Prevalent Cases of Gastroparesis in Italy (2016-2027)
5.2.4.2. Gender based prevalence of Gastroparesis in Italy (2016-2027)
5.2.4.3. Severity based Prevalence (Mild, Moderate, Severe) of Gastroparesis in Italy (2016-2027)
5.2.4.4. Diagnosed and Treatable population of Gastroparesis in Italy (2016-2027)
5.2.5. Spain
5.2.5.1. Total Prevalent Cases of Gastroparesis in Spain (2016-2027)
5.2.5.2. Gender based prevalence of Gastroparesis in Spain (2016-2027)
5.2.5.3. Severity based Prevalence (Mild, Moderate, Severe) of Gastroparesis in Spain (2016-2027)
5.2.5.4. Diagnosed and Treatable population of Gastroparesis in Spain (2016-2027)
5.2.6. United Kingdom
5.2.6.1. Total Prevalent Cases of Gastroparesis in the UK (2016-2027)
5.2.6.2. Gender based prevalence of Gastroparesis in the UK (2016-2027)
5.2.6.3. Severity based Prevalence (Mild, Moderate, Severe) of Gastroparesis in the UK (2016-2027)
5.2.6.4. Diagnosed and Treatable population of Gastroparesis in the UK (2016-2027)
5.3. Japan
5.3.1 Total Prevalent Cases of Gastroparesis in Japan(2016-2027)
5.3.2 Gender based prevalence of Gastroparesis in Japan (2016-2027)
5.3.3 Severity based Prevalence (Mild, Moderate, Severe) of Gastroparesis in Japan (2016-2027)
5.3.4 Diagnosed and Treatable population of Gastroparesis in Japan (2016-2027)
6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed Product
7.1. Metoclopramide ODT
7.1.1. Drug Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Advantages and Disadvantages
7.1.5. Safety and Efficacy
7.1.6. Product Profile
To be continued in report…
8. Emerging Therapies
8.1. Key Cross Competition
8.2. TAK-906: Takeda
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.3. TD-8954 : Theravance Biopharma
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.4. VLY-686: Vanda Pharmaceuticals
8.4.1. Regulatory Milestones
8.4.2. Clinical Development
8.4.3. Product Profile
8.4.4. Clinical Pipeline Activity
8.4.4.1. Ongoing Trials Information
8.5. Relamorelin: Allergan
8.5.1. Regulatory Milestones
8.5.2. Clinical Development
8.5.3. Product Profile
8.5.4. Clinical Pipeline Activity
8.5.4.1. Ongoing Trials Information
To be continued in report…
9. Gastroparesis Market Size
9.1. Key Findings
9.2. Total 7MM Gastroparesis Market Analysis 
9.2.1. Overview of Total Gastroparesis Market 
9.2.2.  Market size of Gastroparesis Market by 7MM (2016-2027)
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.1.1. Total Market Size of Gastroparesis
10.1.2. Market Size of Gastroparesis by Therapies
10.2. Germany Market Size
10.2.1. Total Market Size of Gastroparesis
10.2.2. Market Size of Gastroparesis by Therapies
10.3. France Market Size
10.3.1. Total Market Size of Gastroparesis
10.3.2. Market Size of Gastroparesis by Therapies
10.4. United Kingdom Market Size
10.4.1. Total Market Size of Gastroparesis
10.4.2. Market Size of Gastroparesis by Therapies
10.5. Spain Market Size
10.5.1. Total Market Size of Gastroparesis
10.5.2. Market Size of Gastroparesis by Therapies
10.6. Italy Market Size
10.6.1. Total Market Size of Gastroparesis
10.6.2. Market Size of Gastroparesis by Therapies
10.7. Japan Market Size
10.7.1. Total Market Size of Gastroparesis
10.7.2. Market Size of Gastroparesis by Therapies
11. Market Drivers
12. Market Barriers
13. Report Methodology
13.1. Sources Used
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Table 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Table 2 Gender based prevalence of Gastroparesis in 7MM (2016-2027)
Table 3 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in 7MM (2016-2027)
Table 4 Prevalence of Diagnosed and Treatable population of Gastroparesis in 7MM (2016-2027) 
Table 5 Total prevalence of Gastroparesis in the US  (2016-2027)
Table 6 Gender based prevalence of Gastroparesis in the US (2016-2027)
Table 7 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the US (2016-2027)
Table 8 Prevalence of Diagnosed and Treatable population of  in the US (2016-2027)
Table 9 Total prevalence of Gastroparesis in France (2016-2027)
Table 10 Gender based prevalence of Gastroparesis in France (2016-2027)
Table 11 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Table 12 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Table 13 Total prevalence of Gastroparesis in Germany (2016-2027)
Table 14 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Table 15 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Table 16 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Table 17 Total prevalence of Gastroparesis in Italy (2016-2027)
Table 18 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Table 19 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Table 20 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Table 21 Total prevalence of Gastroparesis in Spain (2016-2027)
Table 22 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Table 23 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Table 24 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Table 25 Total prevalence of Gastroparesis in the UK (2016-2027)
Table 26 Gender based prevalence of Gastroparesis in the UK (2016-2027)
Table 27 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in the UK (2016-2027)
Table 28 Prevalence of Diagnosed and Treatable population of  in the UK (2016-2027)
Table 29 Total prevalence of Gastroparesis in Japan (2016-2027)
Table 30 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Table 31 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Table 32 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Table 33 TAK-906, Clinical Trials by Recruitment status, 2018  
Table 34 TAK-906, Clinical Trials by Zone, 2018
Table 35 TD-8954 , Clinical Trials by Recruitment status, 2018  
Table 36 TD-8954, Clinical Trials by Zone, 2018
Table 37 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Table 40 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 41 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 42 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Table 43 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Table 44 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Table 48 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Table 50 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Table 52 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)

 

Figure 1 Total prevalence of Gastroparesis in 7MM  (2016-2027)
Figure 2 Total prevalence of Gastroparesis in US  (2016-2027)
Figure 3 Gender based prevalence of Gastroparesis in US (2016-2027)
Figure 4 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in US (2016-2027)
Figure 5 Prevalence of Diagnosed and Treatable population of Gastroparesis in US (2016-2027) 
Figure 6 Total prevalence of Gastroparesis in France (2016-2027)
Figure 7 Gender based prevalence of Gastroparesis in France (2016-2027)
Figure 8 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in France (2016-2027)
Figure 9 Prevalence of Diagnosed and Treatable population of  in France (2016-2027)
Figure 10 Total prevalence of Gastroparesis in Germany (2016-2027)
Figure 11 Gender based prevalence of Gastroparesis in Germany (2016-2027)
Figure 12 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Germany (2016-2027)
Figure 13 Prevalence of Diagnosed and Treatable population of  in Germany(2016-2027)
Figure 14 Total prevalence of Gastroparesis in Italy (2016-2027)
Figure 15 Gender based prevalence of Gastroparesis in Italy (2016-2027)
Figure 16 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Italy (2016-2027)
Figure 17 Prevalence of Diagnosed and Treatable population of  in Italy (2016-2027)
Figure 18 Total prevalence of Gastroparesis in Spain (2016-2027)
Figure 19 Gender based prevalence of Gastroparesis in Spain (2016-2027)
Figure 20 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Spain (2016-2027)
Figure 21 Prevalence of Diagnosed and Treatable population of  in Spain (2016-2027)
Figure 22 Total prevalence of Gastroparesis in UK (2016-2027)
Figure 23 Gender based prevalence of Gastroparesis in UK (2016-2027)
Figure 24 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in UK (2016-2027)
Figure 25 Prevalence of Diagnosed and Treatable population of  in UK (2016-2027)
Figure 26 Total prevalence of Gastroparesis in Japan (2016-2027)
Figure 27 Gender based prevalence of Gastroparesis in Japan (2016-2027)
Figure 28 Severity based prevalence of Gastroparesis(Mild, Moderate, Severe) in Japan (2016-2027)
Figure 29 Prevalence of Diagnosed and Treatable population of  in Japan (2016-2027)
Figure 30 TAK-906, Clinical Trials by Recruitment status, 2018  
Figure 31 TAK-906, Clinical Trials by Zone, 2018
Figure 32 TD-8954, Clinical Trials by Recruitment status, 2018  
Figure 33 TD-8954, Clinical Trials by Zone, 2018
Figure 34 Market size of Gastroparesis in 7MM, USD Million (2016-2027)
Figure 35 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 36 United States Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 37 United States Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 38 Germany  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 39 Germany Market Size of Gastroparesis, by Therapy  in USD, Million (2016-2027)
Figure 40 France  Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 41 France Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 42 United Kingdom Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 43 United Kingdom Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 45 Spain Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 47 Italy Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Gastroparesis in USD, Million (2016-2027)
Figure 49 Japan Market Size of Gastroparesis, by Therapy in USD, Million (2016-2027)
Figure 50 Market Drivers
Figure 51 Market Barriers

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*